{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T01:53:33Z","timestamp":1790042013121,"version":"4.0.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004628","name":"MedImmune","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016473","name":"American Regent","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016473","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019040","name":"Respicardia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019040","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["T32HL094301"],"award-info":[{"award-number":["T32HL094301"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005646","name":"Actelion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005646","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014588","name":"Sanofi Pasteur","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014588","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014941","name":"Cytokinetics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014941","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015340","name":"Bayer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.jchf.2021.01.014","type":"journal-article","created":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T18:08:51Z","timestamp":1617818931000},"page":"374-382","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Worsening Heart\u00a0Failure Episodes Outside a Hospital Setting in Heart\u00a0Failure With Preserved Ejection Fraction"],"prefix":"10.1016","volume":"9","author":[{"given":"Muthiah","family":"Vaduganathan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian L.","family":"Claggett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finnian Mc","family":"Causland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebrahim","family":"Barkoudah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Finn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A.","family":"Pfeffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel R.","family":"Rizkala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini","family":"Sabarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.V.","family":"McMurray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay S.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2021.01.014_bib1","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jacc.2009.02.078","article-title":"Palliative care in congestive heart failure","volume":"54","author":"Goodlin","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2021.01.014_bib2","first-page":"816","article-title":"Efficacy of sacubitril\/valsartan relative to a prior decompensation: the PARADIGM-HF Trial","volume":"4","author":"Solomon","year":"2016","journal-title":"J Am Coll Cardiol HF"},{"key":"10.1016\/j.jchf.2021.01.014_bib3","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jacc.2019.11.003","article-title":"Prior heart failure hospitalization, clinical outcomes, and response to sacubitril\/valsartan compared with valsartan in HFpEF","volume":"75","author":"Vaduganathan","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2021.01.014_bib4","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/j.jacc.2017.08.074","article-title":"Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes","volume":"70","author":"Shah","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2021.01.014_bib5","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jacc.2012.09.038","article-title":"Rehospitalization for heart failure: problems and perspectives","volume":"61","author":"Gheorghiade","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2021.01.014_bib6","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1001\/jama.2012.205110","article-title":"Thirty-day readmissions: the clock is ticking","volume":"309","author":"Vaduganathan","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jchf.2021.01.014_bib7","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/jama.2014.6643","article-title":"Recognizing worsening chronic heart failure as an entity and an end point in clinical trials","volume":"312","author":"Butler","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jchf.2021.01.014_bib8","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.ahj.2014.08.002","article-title":"Emergency department visits for heart failure and subsequent hospitalization or observation","volume":"168","author":"Blecker","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.jchf.2021.01.014_bib9","doi-asserted-by":"crossref","first-page":"I4563","DOI":"10.1136\/bmj.l4563","article-title":"Hospital revisits within 30\u00a0days after discharge for medical conditions targeted by the Hospital Readmissions Reduction Program in the United States: National retrospective analysis","volume":"366","author":"Wadhera","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jchf.2021.01.014_bib10","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.jacc.2018.12.034","article-title":"Outpatient intravenous diuretic therapy for heart failure in the United States","volume":"73","author":"Greene","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2021.01.014_bib11","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/eurjhf\/hfq185","article-title":"Trends in heart failure care: Has the incident diagnosis of heart failure shifted from the hospital to the emergency department and outpatient clinics?","volume":"13","author":"Ezekowitz","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2021.01.014_bib12","article-title":"One-year mortality after intensification of outpatient diuretic therapy","volume":"9","author":"Madelaire","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jchf.2021.01.014_bib13","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2021.01.014_bib14","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa0906431","article-title":"Cardiac-resynchronization therapy for the prevention of heart-failure events","volume":"361","author":"Moss","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2021.01.014_bib15","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/ejhf.71","article-title":"Prognosis and response to therapy of first inpatient and outpatient heart failure event in a heart failure clinical trial: MADIT-CRT","volume":"16","author":"Skali","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2021.01.014_bib16","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1056\/NEJMoa1210356","article-title":"Biventricular pacing for atrioventricular block and systolic dysfunction","volume":"368","author":"Curtis","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2021.01.014_bib17","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1056\/NEJMoa032423","article-title":"Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure","volume":"350","author":"Bristow","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2021.01.014_bib18","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1056\/NEJMoa2025797","article-title":"Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure","volume":"384","author":"Teerlink","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2021.01.014_bib19","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2021.01.014_bib20","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2021.01.014_bib21","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2021.01.014_bib22","first-page":"471","article-title":"Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rationale and design of the PARAGON-HF trial","volume":"5","author":"Solomon","year":"2017","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jchf.2021.01.014_bib24","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/1467-9868.00259","article-title":"Semiparametric regression for the mean and rate functions of recurrent events","volume":"62","author":"Lin","year":"2000","journal-title":"J\u00a0R Stat Soc Ser B Stat Methodol"},{"key":"10.1016\/j.jchf.2021.01.014_bib25","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1001\/jamacardio.2017.5250","article-title":"Outpatient worsening heart failure as a target for therapy: a review","volume":"3","author":"Greene","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2021.01.014_bib26","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jacc.2020.05.038","article-title":"Fewer hospitalizations for acute cardiovascular conditions during the COVID-19 pandemic","volume":"76","author":"Bhatt","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2021.01.014_bib27","article-title":"Meta-analysis global group in chronic (MAGGIC) heart failure risk score: validation of a simple tool for the prediction of morbidity and mortality in heart failure with preserved ejection fraction","volume":"7","author":"Rich","year":"2018","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jchf.2021.01.014_bib28","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.jacc.2017.12.048","article-title":"2017 Cardiovascular and stroke endpoint definitions for\u00a0clinical trials","volume":"71","author":"Hicks","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2021.01.014_bib29","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1161\/CIRCULATIONAHA.115.020729","article-title":"Importance of Clinical worsening of heart failure treated in the outpatient setting: evidence from the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart\u00a0Failure Trial (PARADIGM-HF)","volume":"133","author":"Okumura","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2021.01.014_bib30","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1161\/CIRCULATIONAHA.120.047480","article-title":"Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction: a prespecified analysis of DAPA-HF","volume":"142","author":"Docherty","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2021.01.014_bib31","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"Valsartan Heart\u00a0Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2021.01.014_bib32","first-page":"591","article-title":"Re-examination of the BEST trial using composite outcomes, including emergency department visits","volume":"5","author":"Shen","year":"2017","journal-title":"J Am Coll Cardiol HF"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177921000639?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177921000639?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T04:58:33Z","timestamp":1761973113000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177921000639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S2213177921000639"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2021.01.014","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Worsening Heart\u00a0Failure Episodes Outside a Hospital Setting in Heart\u00a0Failure With Preserved Ejection Fraction","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2021.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}